{
    "nctId": "NCT00029224",
    "briefTitle": "Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions",
    "officialTitle": "A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Multiple Myeloma, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Pain score assessed by change from baseline",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Signed informed consent\n* Greater than 18 years of age\n* Proof of breast cancer, multiple myeloma or prostate cancer\n* Diagnosis of at least one cancer-related bone lesion\n* If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception\n* ECOG performance status of 0,1 or 2\n* Ability to read, understand and write English or Spanish language\n* Normal renal function\n* Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria\n* clinically symptomatic brain metastases\n* hypersensitivity to Zometa or other bisphosphonates\n* pregnant or lactating",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}